<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Vivosens Inc.

    Vivosens Inc.

    Vivoo is a wellness assistant that consists of urinalysis test strips and a mobile...

    Vivoo is a wellness assistant that consists of ...

    Amount Raised:    $221,750.00
    Fundraising Status:    EC
    Filing Type:    CF
    Natera, Inc.

    Natera, Inc.

    Natera is a rapidly-growing diagnostics company with proprietary bioinformatics an...

    Natera is a rapidly-growing diagnostics company...

    Filing Type:    PU
    Alector, Inc.

    Alector, Inc.

    We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a n...

    We are a clinical stage biopharmaceutical compa...

    Filing Type:    PU
    Cytonics Corp

    Cytonics Corp

    Cytonics, founded in 2006, is a private research and development company focused o...

    Cytonics, founded in 2006, is a private researc...

    Amount Raised:    $3,300,000.00
    Fundraising Status:    EC
    Filing Type:    CF
    Nemaura Medical Inc.

    Nemaura Medical Inc.

    Nemaura Medical (NASDAQ:NMRD) is a medical technology company which has developed ...

    Nemaura Medical (NASDAQ:NMRD) is a medical tech...

    Filing Type:    PU
    TransMedics Group, Inc.

    TransMedics Group, Inc.

    TransMedics is a commercial-stage medical technology company transforming organ tr...

    TransMedics is a commercial-stage medical techn...

    Filing Type:    PU
    INmune Bio Inc.

    INmune Bio Inc.

    INmune Bio Inc. is a clinical stage biotechnology company that is developing new i...

    INmune Bio Inc. is a clinical stage biotechnolo...

    Filing Type:    PU
    Mustang Bio, Inc.

    Mustang Bio, Inc.

    Mustang Bio, Inc. (“Mustang”), a Fortress Biotech Company, is a clinical-stage...

    Mustang Bio, Inc. (“Mustang”), a Fortress B...

    Filing Type:    PU
    Immutep Limited

    Immutep Limited

    We are a biotechnology company developing novel immunotherapy treatments for cance...

    We are a biotechnology company developing novel...

    Filing Type:    PU
    NextCure, Inc.

    NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering an...

    NextCure is a clinical-stage biopharmaceutical ...

    Filing Type:    PU
    Takeda Pharmaceutical Co., Ltd.

    Takeda Pharmaceutical Co., Ltd.

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-base...

    Takeda Pharmaceutical Company Limited (TSE:4502...

    Filing Type:    PU
    Erytech Pharma S.A.

    Erytech Pharma S.A.

    Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical com...

    Founded in Lyon, France in 2004, ERYTECH is a c...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.